B. Moskovitz

发表

Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain.

C. Rauschkolb, D. Biondi, J. Xiang, 2013, Pain physician.

Post hoc analyses of data from a 90-day clinical trial evaluating the tolerability and efficacy of tapentadol immediate release and oxycodone immediate release for the relief of moderate to severe pain in elderly and nonelderly patients.

D. Biondi, J. Delfgaauw, J. Xiang, 2011, Pain research & management.

Evaluation of study discontinuations with tapentadol inmmediate release and oxycodone immediate release in patients with low back or osteoarthritis pain.

J. Xiang, A. Okamoto, D. Upmalis, 2010, Journal of opioid management.

Tolerability and efficacy of tapentadol extended release in elderly patients ≥ 75 years of age with chronic osteoarthritis knee or low back pain.

D. Biondi, J. Xiang, M. Etropolski, 2015, Journal of Opioid Management.

Meningovascular syphilis after 'appropriate' treatment of primary syphilis.

R. Quintiliani, J. Klimek, N. Fiumara, 1982, Archives of internal medicine.

Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group.

D. Bamberger, G. Cloud, L. Wheat, 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers

Anosh Joseph, J. Barone, V. Velde, 1993, Antimicrobial Agents and Chemotherapy.

Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients.

J. Graybill, C. Tuazon, D. Greenspan, 1998, The American journal of medicine.

A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis.

L. Laine, C. Wilcox, R. Darouiche, 1997, The Journal of infectious diseases.

Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients.

S. Koletar, P. A. Murray, B. Moskovitz, 1997, Clinical therapeutics.

A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis.

A. Degraff, D. Bamberger, T. Platts-Mills, 2000, The New England journal of medicine.

Does Long-Term Itraconazole Prophylaxis Result in In Vitro Azole Resistance in Mucosal Candida albicans Isolates from Persons with Advanced Human Immunodeficiency Virus Infection?

P. Connolly, G. Cloud, L. Wheat, 2000, Antimicrobial Agents and Chemotherapy.

Analgesic treatment for moderate-to-severe acute pain in the United States: patients' perspectives in the Physicians Partnering Against Pain (P3) survey.

S. Mody, B. Mccarberg, C. Benson, 2011, Journal of opioid management.

Clinical adverse effects during ceftriaxone therapy.

B. Moskovitz, 1984, The American journal of medicine.

A multicenter, placebo-controlled, double-blind study of intermittent therapy with itraconazole for the treatment of onychomycosis of the fingernail.

C. R. Daniel, R. Aly, R. Scher, 1997, Journal of the American Academy of Dermatology.

Enhanced Bioavailability of Itraconazole in Hydroxypropylβ-Cyclodextrin Solution versus Capsules in Healthy Volunteers

J. Barone, L. Jessen, A. Hassell, 1998, Antimicrobial Agents and Chemotherapy.

Safety of itraconazole pulse therapy for onychomycosis. An update.

C. R. Daniel, N. Shear, T. Rosen, 1999, Postgraduate medicine.

Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients.

D. Ward, M. Saag, W. J. Fessel, 1999, AIDS research and human retroviruses.

A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group.

M. Saag, J. Sobel, W. J. Fessel, 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group.

M. Saag, J. Sobel, W. Powderly, 1997, The New England journal of medicine.

Food Interaction and Steady‐State Pharmacokinetics of Itraconazole Oral Solution in Healthy Volunteers

J. Barone, L. Jessen, A. Hassell, 1998, Pharmacotherapy.

Continuous itraconazole treatment for onychomycosis and dermatomycosis: an overview of safety.

A. Gupta, P. Doncker, B. Moskovitz, 1999, European journal of dermatology : EJD.

Spiramycin therapy for cryptosporidial diarrhoea in immunocompromised

B. Moskovitz, T. Stanton, J. Kusmierek, 1988 .

Clinical trial of tolerance of HPA-23 in patients with acquired immune deficiency syndrome

B. Moskovitz, 1988, Antimicrobial Agents and Chemotherapy.

Evaluation of Blood Pressure and Heart Rate in Patients with Hypertension Who Received Tapentadol Extended Release for Chronic Pain: A Post Hoc, Pooled Data Analysis

D. Biondi, J. Xiang, M. Etropolski, 2014, Clinical Drug Investigation.

Immediate-release tapentadol or oxycodone for treatment of acute postoperative pain after elective arthroscopic shoulder surgery: a randomized, phase IIIb study.

N. Rosenthal, J. Xiang, C. Benson, 2013, Journal of opioid management.

Physicians' beliefs and likelihood of prescribing opioid tamper-resistant formulations for chronic noncancer pain patients.

D. Turk, H. Wilson, E. Dansie, 2014, Pain medicine.

Tapentadol , oxycodone or placebo for acute pain of vertebral compression fractures : a randomized Phase IIIb study RESEARCH

N. Rosenthal, J. Xiang, G. Vorsanger, 2010 .

Pharmacokinetic model and simulations of dose conversion from immediate- to extended-release tramadol*

D. Skee, G. Vorsanger, B. Moskovitz, 2007, Current medical research and opinion.

Clinicians' attitudes and beliefs about opioids survey (CAOS): instrument development and results of a national physician survey.

D. Turk, H. Wilson, E. Dansie, 2013, The journal of pain : official journal of the American Pain Society.

A post hoc pooled data analysis to evaluate the gastrointestinal tolerability profile of tapentadol extended release (ER) versus oxycodone controlled release (CR) in patients ≥75 years of age

D. Biondi, J. Xiang, M. Etropolski, 2011 .

A post hoc pooled data analysis to evaluate blood pressure (BP) and heart rate (HR) measurements in patients with a current or prior history of hypertension who received tapentadol ER, oxycodone CR, or placebo in chronic pain studies

D. Biondi, J. Xiang, M. Etropolski, 2011 .

Tapentadol extended release (ER) versus oxycodone controlled release (CR) for management of chronic low back or osteoarthritis pain: influence of prior opioid experience on study discontinuations due to constipation, nausea, or vomiting

D. Biondi, J. Xiang, J. Ashworth, 2010 .

Tapentadol extended release (ER) versus oxycodone controlled release (CR) for management of chronic low back or osteoarthritis pain: analyses of study discontinuations due to constipation, nausea, or vomiting

D. Biondi, J. Xiang, M. Etropolski, 2010 .

Ceftriaxone Therapy for Asymptomatic Neurosyphilis: Case Report and Western Blot Analysis of Serum and Cerebrospinal Fluid IGG Response to Therapy

H. Handsfield, E. Hook, S. Lukehart, 1986, Sexually transmitted diseases.

Randomized Trial Tapentadol Immediate Release Versus Oxycodone Immediate Release for Treatment of Acute Low Back Pain

C. Rauschkolb, D. Biondi, J. Xiang, 2013 .

Tapentadol, oxycodone or placebo for acute pain of vertebral compression fractures: a randomized Phase IIIb study.

N. Rosenthal, J. Xiang, G. Vorsanger, 2013, Pain management.